Factors Impacting Health Net Drug Trends - 2003 & Beyond

• More lower cost generics entering market (leveraged by generic initiatives)

  • Augmentin H1’03
  • Monopril/Accupril H1‘03
  • Lotensin H2‘03
  • Welbutrin SR (?)
  • Paxil (?)
  • Flovent H1’04
  • Flonase H1’04
  • Celexa H1’04
  • Cipro H2’04

Previous slide

Next slide

Back to first slide

View graphic version